Mezigdomide Combinations Show Promise in Multiple Myeloma

 The phase I/II CA057-003 trial

opens in a new tab or window presented at the American Society of Hematologyopens in a new tab or window annual meeting showed promising results with novel mezigdomide-based combinations in relapsed or refractory multiple myeloma.

In this exclusive MedPage Today video, David Samuel Dicapua Siegel, MD, of the John Theurer Cancer Center in Hackensack, New Jersey, discusses the potential for this investigational small molecule agent.

Following is a transcript of his remarks:

Mezigdomide, which is the centerpiece of this trial, is a newer derivative of thalidomide. And for those uninformed, the thalidomide derivatives are probably the most important drugs that have been developed in myeloma over the last couple of decades, actually 3 decades.

And so mezigdomideopens in a new tab or window is a molecule that seems to maximize the qualities of thalidomide and the other thalidomide derivatives, both in terms of having direct tumoricidal effects, but also in terms of modulating the way the immune response deals with tumors in general. And so what this trial is, is an effort to maximize the interactions with mezigdomide by targeting some of these other pathways.

Some of the combinations are a little bit more mature than others, and so the data that is going to be presented is on those more mature lines of combinations. And what it shows is that these combinations are both well tolerated. Not to say that there are no toxicities. These thalidomide derivatives, mezigdomide in particular, can cause hematologic toxicities. But there were no surprising signals in terms of using these combinations and having them limited because of unforeseen toxicities.

So that's the way the trial was designed. And what we see is that in this patient population, that we would not have high levels of expectation of durable responses, that we are actually seeing that, and we're seeing it without costing the patients in terms of either hematologic or subjective toxicities that are unacceptable.

https://www.medpagetoday.com/meetingcoverage/ashfuturefocusmm/113557